The Medicines and Health Care Product Regulatory Agency (MHRA) has issued a safety warning in connection with Atomexetine (brand name Straltera). The drug is a prescription medicine used in the treatment of attention deficit and hyperactivity disorder (ADHD) in children aged over 6 years, adolescents and some adults.
Many patients taking Atomexetine experienced small non-important increases in heart rate and blood pressure. A review of information from clinical trials has found that approximately 10% of patients experience larger and more prolonged increases in heart rate and blood pressure which may have clinical implications in some patient groups.
Health professionals have been advised to monitor blood pressure and heart rate in all patients receiving Atomexetine during the course of their treatment.
The agency has warned that Atomexetine should not be used in patients with severe cardiovascular conditions such as severe hypertension, heart failure, inherited heart conditions or disease, heart attack or stroke or cerebral aneurysm.
If any of these issues affect you or if you or a family member has been taking this drug and has suffered from any of the above conditions you may be entitled to claim damages.